TP53 and ovarian serous carcinoma: Parkinson et al. retrospectively analyzed TP53 mutations in cfDNA as biomarker of treatment response for patients with relapse high-grade serous ovarian carcinoma and demonstrated that a decrease of ≤60% in TP53 mutant allele fraction after one cycle of chemotherapy was associated with shorter time to progression (Parkinson et al., 2016).